Chapter one:Site-specific drug delivery using liposomes as carriers 16.Gregoriadis,G.,Ed.,Liposomes as drug carriers,Recent Trends and Progress, John Wiley Sons,New York,1988. 17.Papahadjopoulos,D.,Liposomes as drug carriers,Annu.Rep.Med.Chem.14, 25026019709 ues to murine bladder tumor,J.Urol.,135,612-615,1986. 19.Magin,R.L.and Niesman,M.R.,Temperature-dependent drug release from large mes,Cancer Drug Delivery,1,109-117,1984. 20.Knudsen,R.C Card,D.M.,and Hoffman,W.W.,Protection of guinea pig against local and systemic foot-and-mouth disease after administration of synthetic lipid amine(Avridine)liposomes,Antiviral Res.,6,123-133,1986. 21.Gregoroadid,G.and Senior,J.,The phospholipid component of small unila- circulation,FEBS Lett.,119,43-46.1980. 22.Kiwada,H.,Akimoto,M.,Araki,M.,Tsuji,M.,and Kato,Y.,Application of carriers I.Their preparation and transport of glutathione into the liver Chem synthetic 23.Scherphof,G.,Morselt,H.,Regts,J.,and Wilschut,J.,The involvement of the lipid phase transition in the plasma-induced dissolution of multilamellar phosphatidyl-choline vesicles,Biochem.Biophys.Acta,556,196-207,1979. 24.Citovsky,V.,Blumenthal,R.,and Loyter,A.,Fusion of Sendai virions with phosphatidyl-choline-cholesterol liposomes reflects the viral activity required for fusion with biological membranes,FEBS Lett.,193,135-140,1985 25. Szoka,F.C.and Papahadjopoulos,D.,Comparative properties and methods peparation of lipid vesicles (Liposomes)A.Rv.Biophys.Bioen 26.Mayhew,E.and Papahadjoloulos,D.,Therapeutic uses of liposomes.In Li- posomes.Ostro.M.Ed.Marcel Dekker.New York.1983. 27.Hunt,A.C.Rustum,Y.M.,Mayhew,E.,and Papahadjopoulos,D.,Retention of cytosine arabinoside in mouse lung following intravenous administration in liposomes of different size,Drug.Metab.Dispo.,7,124-128,1979. 28.Heath,T.D.,Fraley,R.T.,and Papahadjopoulos,D.,Antibody targeting of liposomes:cell specificity obtained by conjugation of F(ab)to vesicle surface, Science,210,539-541,1980. 9 Martin,FJ.and Papahadjopoulos,D.,Irreversible coupling of immunoglob- ulin fragments to preformed vesicles,J.Biol.Chem.,257,286-288,1982. 30.Hirano,K.,Hunt,C.A.,Strubbe,A.,and MacGregor,R.D.,Lymphatic trans- port of liposome-encapsulated drugs following i intraperitoneal administra tion-effect of lipid composition,Pharm.Res.,271-278,1985. 31.Nakatsu,K.and Cameron,D.A.,Uptake of liposome-entrapped mannitol by diaphragm,Can.J.Physiol.Pharmacol,57,756-759,1979. 32.Ellens,H.,Morselt,H.,and Scherphof,G.In vio fate of large multilamellar sphingomyelin-cholesterol liposomes after intraperitoneal and intravenous injection into rats,Biochem.Biophys.Acta,674,10-18,1981 33.Allen,T.M.,Murray,L.,MacKeigan,S.,and Shah,M.,Chronic liposome administration in mice:effects on reticuloendothelial I function and tissue dis tribution,Pharmacol.Exp.Ther.,229,267-275,1984
Chapter one: Site-specific drug delivery using liposomes as carriers 27 16. Gregoriadis, G., Ed., Liposomes as drug carriers, Recent Trends and Progress, John Wiley & Sons, New York, 1988. 17. Papahadjopoulos, D., Liposomes as drug carriers, Annu. Rep. Med. Chem. 14, 250–260, 1979. 18. Bassett, J.B., Anderson, R.U., and Tucker, J.R., Use of temperature-sensitive liposomes in the selective delivery of methotrexate and cis-platinum analogues to murine bladder tumor, J. Urol., 135, 612–615, 1986. 19. Magin, R.L. and Niesman, M.R., Temperature-dependent drug release from large unilamellar liposomes, Cancer Drug Delivery, 1, 109–117, 1984. 20. Knudsen, R.C, Card, D.M., and Hoffman, W.W., Protection of guinea pigs against local and systemic foot-and-mouth disease after administration of synthetic lipid amine (Avridine) liposomes, Antiviral Res., 6, 123–133, 1986. 21. Gregoroadid, G. and Senior, J., The phospholipid component of small unilamellar liposomes controls the rate of clearance of entrapped solutes from the circulation, FEBS Lett., 119, 43–46, 1980. 22. Kiwada, H., Akimoto, M., Araki, M., Tsuji, M., and Kato, Y., Application of synthetic liposomes based on acyl amino acids or acyl peptides as drug carriers. I. Their preparation and transport of glutathione into the liver, Chem. Pharm. Bull., 35, 2935–2942, 1987. 23. Scherphof, G., Morselt, H., Regts, J., and Wilschut, J., The involvement of the lipid phase transition in the plasma-induced dissolution of multilamellar phosphatidyl-choline vesicles, Biochem. Biophys. Acta, 556, 196–207, 1979. 24. Citovsky, V., Blumenthal, R., and Loyter, A., Fusion of Sendai virions with phosphatidyl-choline-cholesterol liposomes reflects the viral activity required for fusion with biological membranes, FEBS Lett., 193, 135–140, 1985. 25. Szoka, F.C. and Papahadjopoulos, D., Comparative properties and methods for preparation of lipid vesicles (Liposomes) Annu. Rev. Biophys. Bioeng., 9, 467–508, 1980. 26. Mayhew, E. and Papahadjoloulos, D., Therapeutic uses of liposomes. In Liposomes, Ostro, M., Ed., Marcel Dekker, New York, 1983. 27. Hunt, A.C., Rustum, Y.M., Mayhew, E., and Papahadjopoulos, D., Retention of cytosine arabinoside in mouse lung following intravenous administration in liposomes of different size, Drug. Metab. Dispo., 7, 124–128, 1979. 28. Heath, T.D., Fraley, R.T., and Papahadjopoulos, D., Antibody targeting of liposomes: cell specificity obtained by conjugation of F(ab) to vesicle surface, Science, 210, 539–541, 1980. 29. Martin, F.J. and Papahadjopoulos, D., Irreversible coupling of immunoglobulin fragments to preformed vesicles, J. Biol. Chem., 257, 286–288, 1982. 30. Hirano, K., Hunt, C.A., Strubbe, A., and MacGregor, R.D., Lymphatic transport of liposome-encapsulated drugs following intraperitoneal administration-effect of lipid composition, Pharm. Res., 271–278, 1985. 31. Nakatsu, K. and Cameron, D.A., Uptake of liposome-entrapped mannitol by diaphragm, Can. J. Physiol. Pharmacol., 57, 756–759, 1979. 32. Ellens, H., Morselt, H., and Scherphof, G., In vivo fate of large multilamellar sphingomyelin-cholesterol liposomes after intraperitoneal and intravenous injection into rats, Biochem. Biophys. Acta, 674, 10–18, 1981. 33. Allen, T.M., Murray, L., MacKeigan, S., and Shah, M., Chronic liposome administration in mice: effects on reticuloendothelial function and tissue distribution, J. Pharmacol. Exp. Ther., 229, 267–275, 1984
28 Drug delivery systems,second edition 34.Roerdink,EH.Dijkstra,.Spanjer,H.H and Scherphof.G.L and o int 12335336 198 meswith hepatocytes and Kupffer cels p nd Sch oit,A.J. itive liposon eof large Bi sucinyldioleoy-phosphatidylethano 36 Straub nger,R.M.D uzgunes nd I 1 pH-sen tive li del ulat FEBS Lett1791481541985 very cules 37.Li urdy.Rp d Ma padiat po 03.26627 38. ition in vioo by bilay situated carboby ofl时 disp Res.Com 10.140-146,1983. hal,A.and Gu pta,C.M.Antil nediated targeting of liposomes to ell ir FEBs1et,201L321-326.198 40.e I.N.Les an LD.Henker P.A.,and Blume enthal R Anti I T and Trou riadis,G. ew8k1-292 41.T PAH ents for lipo som-encapsulated drugs,ham. 42.Connor,J.Sullivan,S.,and Huang,L,Monoclonal antibody and liposomes Pharm.Ther,28,341-365,1985. 43.Rah A et al Li otection of adriamycin-induced cardiotoxicity in mice,Cancer Res.40.1532-1537,1980. 44.Olson,F.,Mayhew,E.,Maslow,D.,Rustum,Y.,and Szoka,F.Characterization toxicity nd th 3A Eur.I.Cancer.Clin.Oncol.18.2.167-176.1982 cin encapsulated in liposomes 45.Gabzion.A.Go ren.D.Fuks.Z.Meshorer.A. and Barenholtz.Y.Superio theraneutic activity of lin ome-associated adriamycin in a murine metastatic tumor model,Br.J.Cancer,51,681-689,1985. 46.Wein stein.IN.Magin.R.L Yatvin.M.B and Zaharko.DS.Lir omes and local hyperthermia:selective delivery of methotrexate to heated tumors,Sci- mce.204.188-191.197g 47.Carman-Meakin,B.Kellaway,J.W.,and Farr,S.J.,Aliposomal sustained-release delivery system,Intemational Patent Application No.W 48.Trout,A.,Increased selectivity of drug 14.105.1978. 49.Gregoriadis,G.and Ryman,B.E.Fate of protein-containing lip somes iniect. ed into rats an a roach to the treatment of storage diseases,Eur.J.Biochem. 24.485491.1972 50.Tyrell,D.A.,Heath,T.D.,Colley,C.M.,and Ryman,B.E.,New aspects of liposomes,Biochim.Biophys.Acta,457,259,1976. 51.Gregoriadis,G.,Senior,J.,and Trout,A.,Eds.,Targeting of drugs,NATO-ASI Series A 47.Plenum Press New York and London 1983 52.Gregoriadis,G.,Liposomes in therapeutic and preventive medicine.The de- velopment of drug carrier concept,Ann.N.Y.Acad.Sci.,308,343,1978. 53.Schroit,E.J.,Hart,I.R.,Madsen,J.,and Fidler,IJ.,Selective delivery of drugs encapsulated in liposomes:natural targeting to macrophages involved in various disease states,J.Biol.Response Modifiers,297-100,1983
28 Drug delivery systems, second edition 34. Roerdink, F.H., Dijkstra, J., Spanjer, H.H., and Scherphof, G.L., In vivo and in vitro interaction of liposomes with hepatocytes and Kupffer cells, Biochem. Soc. Trans., 12, 335–336, 1984. 35. Nayar, R. and Schroit, A.J., Generation of pH-sensitive liposomes, use of large unilamellar vesicles containing N-succinyldioleoyl-phosphatidylethanolamine, Biochemistry, 24, 5967–5971, 1985. 36. Straubinger, R.M., Duzgunes, N., and Papahadjopoulos, D., pH-sensitive liposomes mediate cytoplasmic delivery of encapsulated macromolecules, FEBS Lett., 179, 148–154, 1985. 37. Liburdy, R.P. and Magin, R.L., Microwave-stimulated drug release from liposomes, Radiat. Res., 103, 266–275, 1985. 38. Szoka, F.C. and Mayhew, E., Alteration of liposome disposition in vivo by bilayer-situated carbohydrates, Biochem. Biophys. Res. Commun., 110, 140–146, 1983. 39. Singhal, A. and Gupta, C.M., Antibody-mediated targeting of liposomes to red cell in vivo, FEBS Lett., 201, 321–326, 1986. 40. Weinstein, J.N., Lesserman, L.D., Henkert, P.A., and Blumenthal, R., Antibody-mediated targeting of liposomes. In Targeting of Drugs, Gregoriadis, G., Senior, J. and Trout, A., Eds., Plenum Press, New York, 185–202, 1982. 41. Toonan, P.A.H. and Crommelin, D.J.A., Immunoglobulins as targeting agents for liposome-encapsulated drugs, Pharm. Weekbl. Sci. Edition, 269–280, 1983. 42. Connor, J., Sullivan, S., and Huang, L., Monoclonal antibody and liposomes, Pharm. Ther., 28, 341–365, 1985. 43. Rahman, A. et al., Liposomal protection of adriamycin-induced cardiotoxicity in mice, Cancer Res., 40, 1532–1537, 1980. 44. Olson, F., Mayhew, E., Maslow, D., Rustum, Y., and Szoka, F., Characterization, toxicity and therapeutic efficacy of adriamycin encapsulated in liposomes, Eur. J. Cancer. Clin. Oncol., 18, 2, 167–176, 1982. 45. Gabzion, A., Goren, D., Fuks, Z., Meshorer, A., and Barenholtz, Y., Superior therapeutic activity of liposome-associated adriamycin in a murine metastatic tumor model, Br. J. Cancer, 51, 681–689, 1985. 46. Weinstein, J.N., Magin, R.L., Yatvin, M.B., and Zaharko, D.S., Liposomes and local hyperthermia: selective delivery of methotrexate to heated tumors, Science, 204, 188–191, 1979. 47. Carman-Meakin, B., Kellaway, J.W., and Farr, S.J., A liposomal sustained-release delivery system, International Patent Application No. WO 87/01714, 1986. 48. Trout, A., Increased selectivity of drugs by linking to carriers, Eur. J. Cancer, 14, 105, 1978. 49. Gregoriadis, G. and Ryman, B.E., Fate of protein-containing liposomes injected into rats: an approach to the treatment of storage diseases, Eur. J. Biochem., 24, 485–491, 1972. 50. Tyrell, D.A., Heath, T.D., Colley, C.M., and Ryman, B.E., New aspects of liposomes, Biochim. Biophys. Acta, 457, 259, 1976. 51. Gregoriadis, G., Senior, J., and Trout, A., Eds., Targeting of drugs, NATO-ASI Series A, 47, Plenum Press, New York and London, 1983. 52. Gregoriadis, G., Liposomes in therapeutic and preventive medicine. The development of drug carrier concept, Ann. N.Y. Acad. Sci., 308, 343, 1978. 53. Schroit, E.J., Hart, I.R., Madsen, J., and Fidler, I.J., Selective delivery of drugs encapsulated in liposomes: natural targeting to macrophages involved in various disease states, J. Biol. Response Modifiers, 2 ,97–100, 1983
Chapter one:Site-specific drug delivery using liposomes as carriers 29 54.Tavlor.R.L.Williams.D.M.Craven.PC.Gravbil.IR.Drutz.D.I.and Ma- gee,W.E.,Amphotericin B in liposomes:a novel therapy for histoplasmosis Ann.Rev.Respir.Dis.,125,610-611,1982. 55.Lopez-Berestein,G.,Faibstein,V.,Hopfer,R.L Mehta,K.,et al.,Liposomal amphotericin B for the treatment of systemic fungal infections in patients with cancer:a preliminary study,J.Infect.Dis.,151,704-710,1985. 56.Mehta.R.Lopez-Berestein.G.Hopfer.RL.Mills.K.and luliano.RL. Liposomal amphotericin B is toxic to fungal cells but not to mammalian cells, Bi0chim.Biophus.Acta,770230-23482,6,164-167,1984. 57.Juliano,R.L.and Lopez-Berestein,G.New lives for old drugs somal drug delivery systems reduce the toxicity but not the potency of certain chemo theraneutic agents Pharm Tech 6 164-167 1982 58.Sunamoto,J.,Goto,M.,Ida,T.,Hara.K.,Saito,A.,and Tomonaga,A.,Unex- pected tissue distribution of liposomes coated with amylopectin derivatives and succe sful use in the treatment of experin ntal Legionnaires'disease.In Receptor Mediated Targeting of Drugs,Gregoriadis,G.,Poste,G.,Senior,J.,and Trout A Eds Plenum Press New York 359-371 1984 59.Thombre,P.S.and Deodhar,S.D.,Inhibition of liver metastases in murine colon adenocarcinoma by liposomes containing human C-reactive protein crude lymphokines,Cancer Immunol.Immunother.,16,145-150,1984 60.Parant,M.,Parant,F.,Chedid,L,Yapo,A.,Petit,J.F.,and Lederer,E Fate of synthetic immunoadjuvant muramyl dipeptide(C-labeled)in the mouse,Int I.InmnoPharmacol.1.35-47.1979 61.Fogler,W.E.,Wade,R.,Brundish,D.E.,and Fidler,LJ.,Distribution and fate of free and liposome-encapsulated H nor-muramyl dipeptide and H muramyl tripeptide phosphatidyl ethanolamine in mice,J.Immunol.135,1372-1377,1985 62.Fidler,I.J,Sone,S.,Fogler,W.E.,and Barnes,Z.L.,Eradication of spontaneous metastases and activation of alveolar macrophages by intravenous injection of liposomes containing muramyl dipeptide,Proc.Natl.Acad.Sci.USA,78, 1680-1684.1984. 63.Trout,A.,Baurain,R.,Deprez-De Campeneere,D.,Layton,D.,and Masque- lier,M.,DNA,liposomes and proteins as carriers for antitumoral drugs,Recent Results Cancer Res.,75,229,1980. 64.Poste,G.,Bucana,C.,and Fidler,IJ.,Stimulation of host response against metastatic tumors by liposome-encapsulated immunomodulators.In Target- mg of Drugs,Gregoriadis,G.,Senior,.and Trout,A.,Eds.,Plenum Press New York.261-284,1982 65.Gregoriadis,G.,Neerunjub,D.E.,and Hunt,R.,Fate of liposome-associated agents injected into normal and tumor-bearing rodents:attempts to improve localization in tumor cells,Life Sci.,21,357-370,1972. 66.Proffitt,R.T.,Williams,L.E,Presant,C.A.,Uliana,J.A.,Gamble,R.C.,and Baldeschweiler,J.D.,Liposomal blockade of the reticuloendothelial system improved tumor imaging with small unilamellar vesicles,Science,220, 502-505,1983. 67.Stavridis,J.C.,Deliconstantinos,G.Psallidopoulos,M.C.,Armenskas,N.A. Hadjiminas,D.J.,and Hadjiminas,J.,Construction of transferrin-coated lipo- somes for in vivo transport of exogenous DNA to bone marrow erythrocytes in rabbits,J.Exp.Cell Res.,43,546-550,1986. 68.Forssen,E.A.and Tokes,Z.A.,Improved therapeutic benefits of doxorubicin by entrapment in anionic liposomes,Cancer Res.,43,546-550,1983
Chapter one: Site-specific drug delivery using liposomes as carriers 29 54. Taylor, R.L., Williams, D.M., Craven, P.C., Graybil, J.R., Drutz, D.J., and Magee, W.E., Amphotericin B in liposomes: a novel therapy for histoplasmosis, Ann. Rev. Respir. Dis., 125, 610–611, 1982. 55. Lopez-Berestein, G., Faibstein, V., Hopfer, R.L., Mehta, K., et al., Liposomal amphotericin B for the treatment of systemic fungal infections in patients with cancer: a preliminary study, J. Infect. Dis., 151, 704–710, 1985. 56. Mehta, R., Lopez-Berestein, G., Hopfer, R.L., Mills, K., and Juliano, R.L., Liposomal amphotericin B is toxic to fungal cells but not to mammalian cells, Biochim. Biophys. Acta, 770230–23482, 6, 164–167, 1984. 57. Juliano, R.L. and Lopez-Berestein, G., New lives for old drugs: liposomal drug delivery systems reduce the toxicity but not the potency of certain chemotherapeutic agents, Pharm. Tech., 6, 164–167, 1982. 58. Sunamoto, J., Goto, M., Ida, T., Hara. K., Saito, A., and Tomonaga, A., Unexpected tissue distribution of liposomes coated with amylopectin derivatives and successful use in the treatment of experimental Legionnaires’ disease. In Receptor Mediated Targeting of Drugs, Gregoriadis, G., Poste, G., Senior, J., and Trout, A., Eds., Plenum Press, New York, 359–371, 1984. 59. Thombre, P.S. and Deodhar, S.D., Inhibition of liver metastases in murine colon adenocarcinoma by liposomes containing human C-reactive protein crude lymphokines, Cancer Immunol. Immunother., 16, 145–150, 1984. 60. Parant, M., Parant, F., Chedid, L., Yapo, A., Petit, J.F., and Lederer, E., Fate of synthetic immunoadjuvant muramyl dipeptide (C-labeled) in the mouse, Int. J. ImmunoPharmacol., 1, 35–47, 1979. 61. Fogler, W.E., Wade, R., Brundish, D.E., and Fidler, I.J., Distribution and fate of free and liposome-encapsulated H nor-muramyl dipeptide and H muramyl tripeptide phosphatidyl ethanolamine in mice, J. Immunol., 135, 1372–1377, 1985. 62. Fidler, I.J., Sone, S., Fogler, W.E., and Barnes, Z.L., Eradication of spontaneous metastases and activation of alveolar macrophages by intravenous injection of liposomes containing muramyl dipeptide, Proc. Natl. Acad. Sci. USA, 78, 1680–1684, 1984. 63. Trout, A., Baurain, R., Deprez-De Campeneere, D., Layton, D., and Masquelier, M., DNA, liposomes and proteins as carriers for antitumoral drugs, Recent Results Cancer Res., 75, 229, 1980. 64. Poste, G., Bucana, C., and Fidler, I.J., Stimulation of host response against metastatic tumors by liposome-encapsulated immunomodulators. In Targeting of Drugs, Gregoriadis, G., Senior, J., and Trout, A., Eds., Plenum Press, New York, 261–284, 1982. 65. Gregoriadis, G., Neerunjub, D.E., and Hunt, R., Fate of liposome-associated agents injected into normal and tumor-bearing rodents: attempts to improve localization in tumor cells, Life Sci., 21, 357–370, 1972. 66. Proffitt, R.T., Williams, L.E., Presant, C.A., Uliana, J.A., Gamble, R.C., and Baldeschweiler, J.D., Liposomal blockade of the reticuloendothelial system: improved tumor imaging with small unilamellar vesicles, Science, 220, 502–505, 1983. 67. Stavridis, J.C., Deliconstantinos, G., Psallidopoulos, M.C., Armenskas, N.A., Hadjiminas, D.J., and Hadjiminas, J., Construction of transferrin-coated liposomes for in vivo transport of exogenous DNA to bone marrow erythrocytes in rabbits, J. Exp. Cell Res., 43, 546–550, 1986. 68. Forssen, E.A. and Tokes, Z.A., Improved therapeutic benefits of doxorubicin by entrapment in anionic liposomes, Cancer Res., 43, 546–550, 1983
30 Drug delivery systems,second edition 69. Gabzion,A.Dagan,A.Goren,D.Barenholz.Y.,and Fuks,Z Lipo n0元 od c ke and preserved antitu 70. rmacological,toxico therape c ev inma,1985 xorubicin entrapped in car 71 Van Ho md neph P.A., ardiotoxi rommelin,D.LA.,Van Diik.A rubicin app d in stable liposomes in the LOU/M Ws]ra 72.Roe link,E.H.Regts,Van L B.,and Sche hof,G.,Intrah i uptake sly in id ye esicles in rats.Biochim.Biop Acta 70,195-202.198 ellar phospho 73.K L.Chobaniar A.V.and Brecher The nation of 72.12511258197 rese bling HDLin the rat,Biocin m.Biophys 74.Sche t o with high-den s.Biochim.Bioph Acta.,542,296-307.1978. .I.N.and Lese LD.,Liposomes as drug carriers in cancer ,p harmac.Ther,24,207-233.1984. 76.Mufson.D.The s.In The Latest Develor to targ nts in Drug Delivery Sys Pham.Tech.,16-21,1985. 77. Pharmap iects 1993 on.U.et al.PharmacoEconomics,2(6),500,1992. Alvi CR 。Aha ,W.L.Jr.,Waits,V.B.,et al,Thera 0 -encapsulated drugs,Proc.Natl Acad.Sci.USA. 80.Black,C.D.V.,Watson,GJ.,and Ward,RI.The use of pentostam liposome in the chemoth apy of experimental leishmaniasis,Trans.Roy.Soc.Trop.Med. 71550L551077 81.New,RRC.Chance,M.L Thomas,S.C and Peters,W.Antileishmanial s.Naue.272.55-56.1978 83.Gregoriadis,G.and Florence,A.T.,Liposomes in drug delivery,Drugs,45, 15-28.1993. 84.Kimura,T.,Intestinal absorption of liposomally entrapped drugs,Sashin Ig- aku.40.1818_1824.1985 85.Kaledin,V.I,Matienko,N.A.,Nikolin,V.P.,Gruntenko,Y.V.,and Budker,V.G. Intralymphatic administration of liposome-encapsulated drugs to mice,J. Natl Cancer lust 66 881-887 1961 86.Payne,N.I.,Timmins,P.,Ambrose,C.V.,Ward,M.D.,and Ridg v.E.Proli posomes:a novel solution to an old problem,I.Pharm.Sci.,75,325,1986. 87.Chen,C.and Alli,D.,Use of fluidized bed in proliposome manufacturing,J. pham.Sci,76,419,1987. 88.Klibanov,A.L,Khaw,B.A.,Nossiff,N.,O'Donnell,S.M.,et al.,Targeting of macromolecular carriers and liposomes by antibodies to myosin heavy chain, Am.J.Physiol,261,60-65,1991
30 Drug delivery systems, second edition 69. Gabzion, A., Dagan, A., Goren, D., Barenholz, Y., and Fuks, Z., Liposomes as in vivo carriers of adriamycin: reduced cardiac uptake and preserved antitumor activity in mice, Cancer Res., 42, 4734–4739, 1982. 70. Rahman, A., White, G., More, N., and Schein, P.S., Pharmacological, toxicological and therapeutic evaluation in mice of doxorubicin entrapped in cardiolipin liposome, Cancer Res., 45, 796–803, 1985. 71. Van Hoessel, Q.G.C.M., Steerenberg, P.A., Crommelin, D.L.A., Van Djik, A., et al., Reduced cardiotoxicity and nephrotoxicity with preservation of antitumor activity of doxorubicin entrapped in stable liposomes in the LOU/M WsJ rat, Cancer Res., 44, 3698–3705, 1984. 72. Roerdink, F.H., Regts, J., Van Leeuwen, B., and Scherphof, G., Intrahepatic uptake and processing of intravenously injected small unilamellar phospholipid vesicles in rats, Biochim. Biophys. Acta., 770, 195–202, 1984. 73. Krupp, L., Chobanian, A.V., and Brecher, P.J., The in vivo transformation of phospholipid vesicles to a particle resembling HDL in the rat, Biochim. Biophys. Res. Commun., 72, 1251–1258, 1976. 74. Scherphof, G., Roerdink, F., Waite, M., and Parks, J., Disintegration of phosphatidylcholine liposomes in plasma as a result of interaction with high-density lipoproteins, Biochim. Biophys. Acta., 542, 296–307, 1978. 75. Weinstein, J.N. and Leserman, L.D., Liposomes as drug carriers in cancer chemotherapy, Pharmac. Ther., 24, 207–233, 1984. 76. Mufson, D., The application of liposome technology to targeted delivery systems. In The Latest Developments in Drug Delivery Systems Conference Proceedings, Pharm. Tech., 16–21, 1985. 77. Pharmaprojects, 1993. 78. Persson, U. et al., PharmacoEconomics, 2(6), 500, 1992. 79. Alving, C.R., Steck, E.A., Chapman, W.L., Jr., Waits, V.B., et al., Therapy of leishmaniasis: superior efficacies of liposome-encapsulated drugs, Proc. Natl. Acad. Sci. USA, 75, 2959–2963, 1978. 80. Black, C.D.V., Watson, G.J., and Ward, R.J., The use of pentostam liposomes in the chemotherapy of experimental leishmaniasis, Trans. Roy. Soc. Trop. Med. Hyg., 71, 550–552, 1977. 81. New, R.R.C., Chance, M.L., Thomas, S.C., and Peters, W., Antileishmanial activity of antimonials entrapped in liposomes, Nature, 272, 55–56, 1978. 82. Gregoriadis, G., Ed., Liposome Technology, Vols. 1–3, CRC Press, Boca Raton, FL, 1993. 83. Gregoriadis, G. and Florence, A.T., Liposomes in drug delivery, Drugs, 45, 15–28, 1993. 84. Kimura, T., Intestinal absorption of liposomally entrapped drugs, Sashin Igaku, 40, 1818–1824, 1985. 85. Kaledin, V.I., Matienko, N.A., Nikolin, V.P., Gruntenko, Y.V., and Budker, V.G., Intralymphatic administration of liposome-encapsulated drugs to mice, J. Natl. Cancer Inst., 66, 881–887, 1961. 86. Payne, N.I., Timmins, P., Ambrose, C.V., Ward, M.D., and Ridgway, F., Proliposomes: a novel solution to an old problem, J. Pharm. Sci., 75, 325, 1986. 87. Chen, C. and Alli, D., Use of fluidized bed in proliposome manufacturing, J. Pharm. Sci., 76, 419, 1987. 88. Klibanov, A.L., Khaw, B.A., Nossiff, N., O’Donnell, S.M., et al., Targeting of macromolecular carriers and liposomes by antibodies to myosin heavy chain, Am. J. Physiol., 261, 60–65, 1991
Chapter one:Site-specific drug delivery using liposomes as carriers 31 89.Artmann,C.,Roding,J.,Ghyczy,M.,and Pratzel,H.G.,Liposomes from soya phospholipids as percutaneous drug carriers,Arzneimittelforschung,40, 1365-1368,1990. 90.Klibanov,A.L.,Maruyama,K.,Beckerleg,A.M.,Torchilin,V.P.,and Huang 1062142_1481901 91.Maruyama,K.,Holmberg,E.,Kennel,S.J.,Klibanov,A.,Torchilin,V.P.,and Huang,L,Characterization of in vivo immunoliposomes,J.Pharm.Sci.,79, 978-984,1990. 92.Singh,M.,Ghose,T.,Mezei,M.,and Belitsky,P.,Inhibition of human renal cancer by monoclonal antibody,Cancer Lett.,56,97-102,1991. 93.Suzuki,H.,Zelphati,O.,Hildebrand,G.,and Leserman,L.,CD4 and CD7 molecules as targets for drug delivery,Exp.Cell Res.,193,112-119,1991. 94.Shibata,R.,Noguchi,T.,Sato,T.,Akiyoshi,K.,Sunamoto,J.,Shiku,J.,and Nakayama,E.,Induction of in vitro and in vioo anti-tumor responses,Int.J Cancer,48,434442,1991. 95.Classen,I.,Van Rooijen,N.,and Classen,E.,A new method for removal of shndne皮2s士chorCuth P.,and Hengartner,H.,Comparative studies of the preparation of immuno- liposomes,Biochim.Biophys.Acta,1026,69-79,1990. 97.Matzku,S.,Krempel,H.,Weckenmann,H.,Sinn,H.,and Stricker,H.,Tu- motargeting with antibody-coupled liposomes,Cancer Immunol.Immunoth- 98.Watanabe,M.,Pesando,J.M.,and Hakomori,S.,Effect of liposomes contain- ing sodium butyrate conjugated with anti-CD19,Cancer Res.,50,3245-3248 1990. 99.Barenolz,Y.and Haran,G.,U.S.Patent 5,192,549. 100.Hayakawa,E.,Kato,Y.,Watanabe,K.,et al.,Japanese Patent 04,244,018. 101.Maitani,Y.,Asane,S.,Takahashi,S.,Nakagaki,M.,and Nagai,T.,Permeability of insulin entrapped in liposomes,Chem.Pharm.Bull.(Tokyo),40,1569-1572 1992. 102.Pajean,M.,Huc,A.,and Herbage,D.,Stabilization of liposomes with collagen, 1mt.L.Pham.77,31-40.1991. 103.Patel,H.M.,Serum apsonins and liposomes,Crit.Rev.Ther.Drug Carrier Syst. 9.39-90.1992 104.Choi.YW.and Rogers.I.A.Characterization of distribution behavior of 2 imidazolines,J.Pharm.Sci.,80,757-760,1991. 105.Foldvari,M.,Mezei,C.,and Mezei,M.,Intracellular delivery of drugs by liposomes,J.Pharm.Sci.,80,1020-1028,1991. 106.Michel,C.,Purmann,T.,Mentrup,E.,Seiller,E,and Kreuter,J.,Effect of liposomes on percutaneous penetration,Int.J.Pharm.(Amst.),84,93-105,1992 107. Taylor,K.M.G.and Farr,S.J.,Liposomes for drug delivery to the respiratory tract,Drug Dev.Ind.Pharm.,19,123-142,1993 108.Waldrep,J.C.,Scherer,P.W.,Keyhani,K.,and Knight,V.,Cyclosporin A lipo- some aerosol particle size and calculated respiratory deposition,Int.J.Pharm. (Amst.,97,205-212,1993. 109.Gregoriadis,G.Liposomes:a tale of drug targeting,J.Drug Targeting,1,3-6, 1993
Chapter one: Site-specific drug delivery using liposomes as carriers 31 89. Artmann, C., Roding, J., Ghyczy, M., and Pratzel, H.G., Liposomes from soya phospholipids as percutaneous drug carriers, Arzneimittelforschung, 40, 1365–1368, 1990. 90. Klibanov, A.L., Maruyama, K., Beckerleg, A.M., Torchilin, V.P., and Huang, L., Activity of amphipathic poly(ethylene glycol) 5000 to prolong the circulation time of liposomes depends on the liposome site, Biochim. Biophys. Acta., 1062, 142–148, 1991. 91. Maruyama, K., Holmberg, E., Kennel, S.J., Klibanov, A., Torchilin, V.P., and Huang, L., Characterization of in vivo immunoliposomes, J. Pharm. Sci., 79, 978–984, 1990. 92. Singh, M., Ghose, T., Mezei, M., and Belitsky, P., Inhibition of human renal cancer by monoclonal antibody, Cancer Lett., 56, 97–102, 1991. 93. Suzuki, H., Zelphati, O., Hildebrand, G., and Leserman, L., CD4 and CD7 molecules as targets for drug delivery, Exp. Cell Res., 193, 112–119, 1991. 94. Shibata, R., Noguchi, T., Sato, T., Akiyoshi, K., Sunamoto, J., Shiku, J., and Nakayama, E., Induction of in vitro and in vivo anti-tumor responses, Int. J. Cancer, 48, 434–442, 1991. 95. Classen, I., Van Rooijen, N., and Classen, E., A new method for removal of mononuclear phagocytes, J. Immunol. Methods, 134, 153–161, 1990. 96. Schwendener, R.A., Trub, T., Schott, H., Langhals, H., Barth, R.F., Groscurth, P., and Hengartner, H., Comparative studies of the preparation of immunoliposomes, Biochim. Biophys. Acta, 1026, 69–79, 1990. 97. Matzku, S., Krempel, H., Weckenmann, H., Sinn, H., and Stricker, H., Tumor-targeting with antibody-coupled liposomes, Cancer Immunol. Immunother., 31, 285–291, 1990. 98. Watanabe, M., Pesando, J.M., and Hakomori, S., Effect of liposomes containing sodium butyrate conjugated with anti-CD19, Cancer Res., 50, 3245–3248, 1990. 99. Barenolz, Y. and Haran, G., U.S. Patent 5,192,549. 100. Hayakawa, E., Kato, Y., Watanabe, K., et al., Japanese Patent 04,244,018. 101. Maitani, Y., Asane, S., Takahashi, S., Nakagaki, M., and Nagai, T., Permeability of insulin entrapped in liposomes, Chem. Pharm. Bull. (Tokyo), 40, 1569–1572, 1992. 102. Pajean, M., Huc, A., and Herbage, D., Stabilization of liposomes with collagen, Int. J. Pharm., 77, 31–40, 1991. 103. Patel, H.M., Serum apsonins and liposomes, Crit. Rev. Ther. Drug Carrier Syst., 9, 39–90, 1992. 104. Choi, Y.W. and Rogers, J.A., Characterization of distribution behavior of 2- imidazolines, J. Pharm. Sci., 80, 757–760, 1991. 105. Foldvari, M., Mezei, C., and Mezei, M., Intracellular delivery of drugs by liposomes, J. Pharm. Sci., 80, 1020–1028, 1991. 106. Michel, C., Purmann, T., Mentrup, E., Seiller, E., and Kreuter, J., Effect of liposomes on percutaneous penetration, Int. J. Pharm. (Amst.), 84, 93–105, 1992. 107. Taylor, K.M.G. and Farr, S.J., Liposomes for drug delivery to the respiratory tract, Drug Dev. Ind. Pharm., 19, 123–142, 1993. 108. Waldrep, J.C., Scherer, P.W., Keyhani, K., and Knight, V., Cyclosporin A liposome aerosol particle size and calculated respiratory deposition, Int. J. Pharm. (Amst.), 97, 205–212, 1993. 109. Gregoriadis, G., Liposomes: a tale of drug targeting, J. Drug Targeting, 1, 3–6, 1993